title: [A retrospective study of the efficacy and toxicity of irinotecan in combination with nedaplatin versus irinotecan in combination with cisplatin as salvage treatment in refractory or relapsed small cell lung cancer].
abstract: OBJECTIVE
  At present no standard second-line combination has been established for recurrent small cell lung cancer (SCLC). Therefore we evaluate the efficacy and safety of irinotecan in combination with nedaplatin/cisplatin against refractory or relapsed small cell lung cancer.
  
  
  METHODS
  In this retrospective study, we analyzed the data of 1,140 patients who diagnosed small cell lung cancer at our hospital from April 2009 to April 2012. Of all the patients, 34 patients were treated with irinotecan and nedaplatin (irinotecan 60 mg/m2 on days 1, 8 nedaplatin 85 mg/m2 day 1, every 3 weeks) , and 20 patients were treated with irinotecan and cisplatin (irinotecan 60 mg/m2 on days 1, 8 cisplatin 75 mg/m2 day 1, every 3 weeks) as the second-line treatment. Prognostic factors of overall survival (OS) were estimated by Kaplan-Meier and Cox's Regression-proportional hazards model.
  
  
  RESULTS
  Of all the 54 eligible patients, median progression free survival (PFS) was 4.9 months, and median OS was 13.3 months. Median PFS was 5.4 months for irinotecan plus nedaplatin (IN) and 4.9 months for irinotecan plus cisplatin (IC), respectively (P=0.465). Median OS was 14.3 months and 13.3 months, respectively (P=0.704). In multivariate analysis, ECOG PS, number of metastases and cycles of chemotherapy were independent prognostic factors. The toxicities were mild, while toxicity profile was slightly different for each of the arms: hematologic toxicity was higher in IN group, and diarrhea was higher in IC group.
  
  
  CONCLUSIONS
  Irinotecan plus platinum is effective and tolerable for refractory and relapsed small cell lung cancer. Irinotecan plus nedaplatin is non-inferior to irinotecan plus cisplatin in terms of efficacy and safety.
authors.affiliation: Department of Medical Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences and Peking Union Medical  College, Beijing 100021, China.
authors.forename: Shufei
authors.initials: S
authors.lastname: Yu
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Xingsheng
authors.initials: X
authors.lastname: Hu
authors.forename: Hongyu
authors.initials: H
authors.lastname: Wang
authors.forename: Xuezhi
authors.initials: X
authors.lastname: Hao
authors.forename: Jianping
authors.initials: J
authors.lastname: Xu
authors.forename: Junling
authors.initials: J
authors.lastname: Li
authors.forename: Xiangru
authors.initials: X
authors.lastname: Zhang
authors.forename: Yuankai
authors.initials: Y
authors.lastname: Shi
mesh_terms: D000328:Adult; D000368:Aged; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D016879:Salvage Therapy; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D009944:Organoplatinum Compounds; D000077146:Irinotecan; C053989:nedaplatin; D002945:Cisplatin; D002166:Camptothecin
references.citation: Crit Rev Oncol Hematol. 2004 Feb;49(2):119-33
references.pmid: 15012973
references.citation: J Clin Oncol. 1992 Aug;10(8):1225-9
references.pmid: 1321891
references.citation: Crit Rev Oncol Hematol. 2002 Jun;42(3):317-25
references.pmid: 12050023
references.citation: Clin Cancer Res. 2012 Feb 15;18(4):1138-45
references.pmid: 22228633
references.citation: N Engl J Med. 2002 Jan 10;346(2):85-91
references.pmid: 11784874
references.citation: Gan To Kagaku Ryoho. 1995 Jun;22(7):889-93
references.pmid: 7793995
references.citation: Toxicol Lett. 1990 Jun;52(1):15-24
references.pmid: 2356567
references.citation: Asian Pac J Cancer Prev. 2011;12(4):1055-9
references.pmid: 21790251
references.citation: J Clin Oncol. 2009 May 20;27(15):2530-5
references.pmid: 19349543
references.citation: Cancer Chemother Pharmacol. 2013 Feb;71(2):345-50
references.pmid: 23124649
references.citation: N Engl J Med. 1999 Jan 28;340(4):265-71
references.pmid: 9920950
references.citation: Semin Oncol. 2003 Feb;30(1):72-8
references.pmid: 12635091
references.citation: J Clin Oncol. 1992 Mar;10(3):484-98
references.pmid: 1311028
references.citation: Anticancer Res. 2006 Jan-Feb;26(1B):777-81
references.pmid: 16739353
references.citation: Oncology. 1996 Mar-Apr;53(2):169-72
references.pmid: 8604245
references.citation: Eur J Cancer. 1993;29A(12):1720-2
references.pmid: 8398301
references.citation: J Clin Oncol. 2006 Oct 1;24(28):4539-44
references.pmid: 17008692
references.citation: J Clin Oncol. 1999 Feb;17(2):658-67
references.pmid: 10080612
references.citation: Semin Oncol. 1997 Dec;24(6 Suppl 20):S20-27-S20-33
references.pmid: 9425958
references.citation: Eur J Cancer. 1994;30A(8):1058-60
references.pmid: 7654428
references.citation: Clin Cancer Res. 2001 Jan;7(1):202-9
references.pmid: 11205910
references.citation: J Clin Oncol. 2003 Apr 15;21(8):1550-5
references.pmid: 12697880